Nuvation Bio Inc. (NUVB): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$1.74M

Year ended 2025-12-31

$2.15M

Trailing 12 months to 2026-06-30

+106.0%

3-year compound annual growth

+76.0%

5-year compound annual growth

2020-12-31 Depreciation & Amortization (USD) 2025-12-31

Period ended	Depreciation & Amortization	Change YoY	Source filing
2025-12-31	$1.74M	+154.6%	2026-03-02, From 2025-01-01
2024-12-31	$683.0K	+207.7%	2026-03-02, From 2024-01-01
2023-12-31	$222.0K	+11.6%	2025-03-06, From 2023-01-01
2022-12-31	$199.0K	+8.2%	2024-02-29, From 2022-01-01
2021-12-31	$184.0K	+78.6%	2023-03-15, From 2021-01-01
2020-12-31	$103.0K	n/a	2022-02-28, From 2020-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Depreciation & Amortization	Change YoY
Nuvation Bio Inc. (NUVB)	2025-12-31	$1.74M	+154.6%
Enanta Pharmaceuticals Inc (ENTA)	2025-09-30	$4.59M	+96.3%
Spero Therapeutics, Inc. (SPRO)	2025-12-31	$0	-100.0%
Aytu Biopharma, Inc (AYTU)	2026-06-30	$3.93M	-26.9%
Rockwell Medical, Inc. (RMTI)	2025-12-31	$2.19M	+0.6%
Viridian Therapeutics, Inc. (VRDN)	2025-12-31	$460.0K	-14.8%
Nektar Therapeutics (NKTR)	2025-12-31	$1.03M	-76.6%
Assembly Biosciences, Inc. (ASMB)	2025-12-31	$129.0K	0.0%
Bicycle Therapeutics PLC (BCYC)	2025-12-31	$6.42M	-10.5%

Compare NUVB, ENTA, SPRO, AYTU side by side · Screen every company in Pharmaceutical Preparations ↗